Maria Rossi

ID: 999998

1954 Nov 11 (67 y.o)

Treatment for

Active principle

Drug name (optional)

As needed medication

Therapy line №

Start date (authored-On)

Drug to be taken at the hospital

End date

Administration time

Note/constraint

Dosage

Delete row Add row “Administration time”

Dosage

Select type of scheduling

Every

For

Then stop for

Mon

Tue

Wed

Thu

Fri

Sat

Sun

In case of (optional):

Start date (authored-On)

Initial dose

Then

Every

Maximum dose

Per

Bound duration (no more than)

Survival model

Model for predicting Overall Survival (OS) for Melanoma patient treated with Imunnotherapy. Predicted survival graphs will be presented for Nivolumab and Nivolumab+Ipilimumab

View

Response model

Model for predicting response to the treatment for Melanoma patient treated with Imunnotherapy. Predicted probabilities of having response will presented for Nivolumab compared to Nivolumab+Ipilimumab

View

Probability of Survival

Survival prediction feature importance

Baseline information

WHO score

ECOG grade 0
LDH level

265 U/L
S100b

Normal
BRAF mutation

NO

Primary melanoma

Location primary tumor

Head and neck
Type of melanoma

Superficial spreading
Breslow thickness in millimeters

1.02 mm
Ulceration

NO
Dermal mitoses

1 or more mitotic figure per mm2
Satellitosis / in-transits metastases

Satellitosis

Metastases

Lymph node metastases (macroscopic)

NO
Distance metastases

YES
Total number of metastases

Multiple
Metastasis site

Lung

Nivolumab

Probability for response to treatment with Nivolumab — 0.85
Nivolumab + Ipilimumab

Probability for response to treatment with Nivolumab + Ipilimumab — 0.7

Response prediction feature importance

Baseline information

WHO score

ECOG grade 0
LDH level

265 U/L
S100b

Normal
BRAF mutation

NO

Primary melanoma

Location primary tumor

Head and neck
Type of melanoma

Superficial spreading
Breslow thickness in millimeters

1.02 mm
Ulceration

NO
Dermal mitoses

1 or more mitotic figure per mm2
Satellitosis / in-transits metastases

Satellitosis

Metastases

Lymph node metastases (macroscopic)

NO
Distance metastases

YES
Total number of metastases

Multiple
Metastasis site

Lung

Filter by questionnairie

Filter by

Date

January 2020

Insomnia Severity Index

12-01-2020

17 of 22 points

Normal

QoL. EORTC QLQ-C30

12-01-2020

View report

PHQ-9

11-01-2020

24 of 27 points

Severe

PHQ-9

08-01-2020

15 of 27 points

Moderately severe

PHQ-9

04-01-2020

9 of 27 points

Mild

PHQ-9

01-01-2020

3 of 27 points

Non – Minimal

17 points

Result — clinical insomnia moderate intensity

Difficulty falling asleep in past 2 weeks

Moderate
Difficulty staying asleep in past 2 weeks

Mild
Problem waking up too early in past 2 weeks

Severe
How satisfied/dissatisfied are you with your current sleep pattern?

Moderate satisfied
To what extent do you consider your sleep problem to interfere with your daily functioning (e.g., daytime fatigue, concentration, memory, mood, etc)

Much
How noticeable to others do you think your sleeping problem is in terms of impairing the quality of your life?

Somewhat
How worried/distressed are you about your current sleep problems?

Very much

WHO score

LDH level

S100b

BRAF mutation

Location primary tumor

Type of melanoma

Breslow thickness in millimeters

Ulceration

Dermal mitoses

Satellitosis / in-transits metastases

Lymph node metastases (macroscopic)

Distance metastases

Total number of metastases

Metastasis site

WHO score

LDH level

S100b

BRAF mutation

Location primary tumor

Type of melanoma

Breslow thickness in millimeters

Ulceration

Dermal mitoses

Satellitosis / in-transits metastases

Lymph node metastases (macroscopic)

Distance metastases

Total number of metastases

Metastasis site